Skip to content

Dare Bioscience, Inc.: 10-Q filed 2020-11-12

What Dare Bioscience, Inc. reported in its quarterly report filed 2020-11-12 (fiscal Q3 2020): 32 published measures, 93 facts as tagged in accession 0001401914-20-000118.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-12
Fiscal period
fiscal Q3 2020
Accession
0001401914-20-000118 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Dare Bioscience, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-307,661,742USD
At 2019-12-317,442,788USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-309,047,630USD
At 2019-12-317,001,962USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30-1,385,888USD
At 2020-06-30311,255USD
At 2020-03-313,214,183USD
At 2019-12-31440,826USD
At 2019-09-301,809,992USD
At 2019-06-305,083,055USD
At 2019-03-313,780,369USD
At 2018-12-316,726,620USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-305,389,414USD
At 2019-12-314,780,107USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-7,582,808USD92
2020-01-01 to 2020-09-30-18,959,268USD274
2020-04-01 to 2020-06-30-7,124,213USD91
2020-01-01 to 2020-03-31-4,252,248USD91
2019-07-01 to 2019-09-30-3,393,078USD92
2019-01-01 to 2019-09-30-10,397,367USD273
2019-04-01 to 2019-06-30-3,952,450USD91
2019-01-01 to 2019-03-31-3,051,840USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-16,041,176USD274
2019-01-01 to 2019-09-30-9,506,797USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-09-3015,246USD274
2019-01-01 to 2019-09-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-3016,675,911USD274
2019-01-01 to 2019-09-305,151,702USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-15,246USD274
2019-01-01 to 2019-09-300USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-62,989,323USD
At 2019-12-31-44,023,191USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-3042,349USD
At 2019-12-3163,531USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-30542,582USD274
2019-01-01 to 2019-09-30344,712USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-7,581,822USD92
2020-01-01 to 2020-09-30-18,961,722USD274
2019-07-01 to 2019-09-30-3,418,549USD92
2019-01-01 to 2019-09-30-10,484,070USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-306,984,436USD
At 2019-12-316,443,932USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-307,964,666USD
At 2019-12-315,612,406USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-301,555,307USD
At 2019-12-311,083,183USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-307,581,822USD92
2020-01-01 to 2020-09-3018,961,722USD274
2019-07-01 to 2019-09-303,418,549USD92
2019-01-01 to 2019-09-3010,484,070USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-306,203,753USD92
2020-01-01 to 2020-09-3014,131,007USD274
2019-07-01 to 2019-09-301,966,230USD92
2019-01-01 to 2019-09-306,172,192USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3033,602,516shares
At 2019-12-3119,683,401shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-09-305,389,414USD
At 2019-12-314,780,107USD
At 2019-09-302,435,120USD
At 2018-12-316,805,889USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-09-30-112,807USD
At 2019-12-31-102,625USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-09-30493,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-09-30634,957USD
At 2019-12-31935,325USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-09-302,454,048USD
At 2019-12-312,098,653USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-18,959,268USD274
2019-01-01 to 2019-09-30-10,397,367USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-7,588,999USD92
2020-01-01 to 2020-09-30-18,976,313USD274
2019-07-01 to 2019-09-30-3,408,456USD92
2019-01-01 to 2019-09-30-11,202,635USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-7,589,671USD92
2020-01-01 to 2020-09-30-18,966,131USD274
2019-07-01 to 2019-09-30-3,393,078USD92
2019-01-01 to 2019-09-30-11,186,961USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,353,069USD92
2020-01-01 to 2020-09-304,772,382USD274
2019-07-01 to 2019-09-301,318,986USD92
2019-01-01 to 2019-09-303,903,545USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-09-3036,428USD274
2019-01-01 to 2019-09-303,491USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-986USD92
2020-01-01 to 2020-09-302,454USD274
2019-07-01 to 2019-09-3025,471USD92
2019-01-01 to 2019-09-3086,703USD273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2020-07-01 to 2020-09-30111,000USD92
2020-01-01 to 2020-09-30349,000USD274
2019-07-01 to 2019-09-3028,000USD92
2019-01-01 to 2019-09-3081,000USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-30472,124USD274
2019-01-01 to 2019-09-30-107,463USD273

Inspect the source

Entity
Dare Bioscience, Inc. / CIK 0001401914
Captured
2026-09-20T08:00:44.110Z
SEC response SHA-256
1a9e5d436251c8650231f065c4c293fc1bb2b6e8877619128801af21ceea9ac3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001401914.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))